ADC Therapeutics (NYSE:ADCT) Reaches New 12-Month High Following Strong Earnings

ADC Therapeutics SA (NYSE:ADCT)’s stock price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company traded as high as $4.95 and last traded at $4.7950, with a volume of 1561459 shares changing hands. The stock had previously closed at $4.23.

The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.23.

ADC Therapeutics News Summary

Here are the key news stories impacting ADC Therapeutics this week:

• Positive Sentiment: Q4 and FY results topped expectations: ADC reported better‑than‑expected EPS (loss narrower than consensus) and product revenues, with Q4 net product revenue of ~$22.3M and full‑year product revenue of ~$73.6M — evidence of commercial traction for ZYNLONTA. PR Newswire: Financial Results
• Positive Sentiment: Profitability metrics beat estimates: reported EPS was materially better than Street forecasts (beats of ~$0.23 on one consensus), which traders typically reward. Zacks: Q4 Results
• Positive Sentiment: Commercial and clinical catalysts reaffirmed: management outlined a $600M–$1B peak revenue target for ZYNLONTA and reiterated progress on LOTIS‑5 and LOTIS‑7 (LOTIS‑5 Phase 3 topline due Q2 2026; full data for both by year‑end 2026) — upcoming readouts are major potential upside events. Seeking Alpha: Commercial/Clinical Outlook
• Neutral Sentiment: Balance sheet and financing: cash and equivalents of ~$261.3M support operations with an expected runway into at least 2028; a recent amendment to a HealthCare Royalty financing deal was announced to increase strategic flexibility — lowers near‑term financing risk but details determine net impact. PR Newswire: Cash & Financing
• Negative Sentiment: Company remains unprofitable and analysts still expect negative EPS for the year; revenue base is growing but loss profile and dependency on clinical readouts keep risk high. Earnings Call Transcript

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ADCT shares. Royal Bank Of Canada reissued an “outperform” rating and set a $5.00 price target on shares of ADC Therapeutics in a report on Wednesday, December 3rd. Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of ADC Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Trading of ADC Therapeutics

Institutional investors have recently made changes to their positions in the stock. Engineers Gate Manager LP bought a new position in shares of ADC Therapeutics in the fourth quarter valued at approximately $43,000. AQR Capital Management LLC lifted its position in ADC Therapeutics by 42.2% in the fourth quarter. AQR Capital Management LLC now owns 206,576 shares of the company’s stock worth $729,000 after purchasing an additional 61,324 shares during the period. Cantor Fitzgerald L. P. bought a new position in ADC Therapeutics during the 4th quarter valued at $353,000. Jump Financial LLC boosted its stake in ADC Therapeutics by 1,299.8% during the 4th quarter. Jump Financial LLC now owns 162,250 shares of the company’s stock valued at $573,000 after purchasing an additional 150,659 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of ADC Therapeutics by 25.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company’s stock valued at $166,000 after purchasing an additional 9,537 shares during the period. 41.10% of the stock is owned by institutional investors and hedge funds.

ADC Therapeutics Trading Up 13.4%

The firm has a 50-day moving average price of $3.89 and a 200-day moving average price of $3.87. The company has a market capitalization of $594.00 million, a price-to-earnings ratio of -3.31 and a beta of 1.92.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.